Go Pro
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Longeveron Inc. stock logo
LGVN
Longeveron
$2.80
-3.8%		$6.46
$2.30
▼
$12.30
$8.91M-0.25228,611 shs38,553 shs
MetaVia Inc. stock logo
MTVA
MetaVia
$1.65
+1.3%		$1.58
$0.97
▼
$14.85
$8.52M0.941.44 million shs13,997 shs
OSR Holdings, Inc. stock logo
OSRH
OSR
$0.22
-14.2%		$0.32
$0.08
▼
$0.91
$7.83M0.496.06 million shs166,659 shs
Valion Bio, Inc. Common Stock stock logo
VBIO
Valion Bio, Inc. Common Stock
$2.97
-14.7%		$4.79
$2.05
▼
$78.75
$2.64M1.79218,378 shs607,052 shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Longeveron Inc. stock logo
LGVN
Longeveron
+11.92%+7.38%-57.21%-59.41%-63.44%
MetaVia Inc. stock logo
MTVA
MetaVia
0.00%+2.52%-0.61%+13.99%-85.89%
OSR Holdings, Inc. stock logo
OSRH
OSR
+6.17%+36.84%+123.18%-22.16%-60.61%
Valion Bio, Inc. Common Stock stock logo
VBIO
Valion Bio, Inc. Common Stock
+27.47%+56.05%-12.45%-74.92%-95.42%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Longeveron Inc. stock logo
LGVN
Longeveron
$2.80
-3.8%		$6.46
$2.30
▼
$12.30
$8.91M-0.25228,611 shs38,553 shs
MetaVia Inc. stock logo
MTVA
MetaVia
$1.65
+1.3%		$1.58
$0.97
▼
$14.85
$8.52M0.941.44 million shs13,997 shs
OSR Holdings, Inc. stock logo
OSRH
OSR
$0.22
-14.2%		$0.32
$0.08
▼
$0.91
$7.83M0.496.06 million shs166,659 shs
Valion Bio, Inc. Common Stock stock logo
VBIO
Valion Bio, Inc. Common Stock
$2.97
-14.7%		$4.79
$2.05
▼
$78.75
$2.64M1.79218,378 shs607,052 shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Longeveron Inc. stock logo
LGVN
Longeveron
+11.92%+7.38%-57.21%-59.41%-63.44%
MetaVia Inc. stock logo
MTVA
MetaVia
0.00%+2.52%-0.61%+13.99%-85.89%
OSR Holdings, Inc. stock logo
OSRH
OSR
+6.17%+36.84%+123.18%-22.16%-60.61%
Valion Bio, Inc. Common Stock stock logo
VBIO
Valion Bio, Inc. Common Stock
+27.47%+56.05%-12.45%-74.92%-95.42%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Longeveron Inc. stock logo
LGVN
Longeveron
2.00
Hold$80.002,759.19% Upside
MetaVia Inc. stock logo
MTVA
MetaVia
2.00
Hold$20.001,111.39% Upside
OSR Holdings, Inc. stock logo
OSRH
OSR
1.00
SellN/AN/A
Valion Bio, Inc. Common Stock stock logo
VBIO
Valion Bio, Inc. Common Stock
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest VBIO, MTVA, LGVN, and OSRH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/8/2026
Longeveron Inc. stock logo
LGVN
Longeveron
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/25/2026
Longeveron Inc. stock logo
LGVN
Longeveron
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/11/2026
Longeveron Inc. stock logo
LGVN
Longeveron
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/28/2026
Longeveron Inc. stock logo
LGVN
Longeveron
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/21/2026
MetaVia Inc. stock logo
MTVA
MetaVia
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/17/2026
Valion Bio, Inc. Common Stock stock logo
VBIO
Valion Bio, Inc. Common Stock
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/10/2026
MetaVia Inc. stock logo
MTVA
MetaVia
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
7/9/2026
Longeveron Inc. stock logo
LGVN
Longeveron
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
(Data available from 9/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Longeveron Inc. stock logo
LGVN
Longeveron
$1.20M7.44N/AN/A$2.47 per share1.13
MetaVia Inc. stock logo
MTVA
MetaVia
N/AN/AN/AN/A$2.31 per shareN/A
OSR Holdings, Inc. stock logo
OSRH
OSR
$1.81M4.33N/AN/A$3.56 per share0.06
Valion Bio, Inc. Common Stock stock logo
VBIO
Valion Bio, Inc. Common Stock
$780K3.39N/AN/A$166.26 per share0.02
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Longeveron Inc. stock logo
LGVN
Longeveron
-$22.70M-$9.90N/AN/AN/A-1,977.59%-223.19%-150.20%11/3/2026 (Estimated)
MetaVia Inc. stock logo
MTVA
MetaVia
-$12.97M-$3.23N/AN/AN/AN/A-209.67%-107.91%11/5/2026 (Estimated)
OSR Holdings, Inc. stock logo
OSRH
OSR
-$27.06M-$0.37N/AN/AN/A-593.15%-8.36%-6.24%N/A
Valion Bio, Inc. Common Stock stock logo
VBIO
Valion Bio, Inc. Common Stock
-$8.88M-$159.25N/AN/AN/AN/A-193.17%-67.10%N/A

Latest VBIO, MTVA, LGVN, and OSRH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
OSR Holdings, Inc. stock logo
OSRH
OSR
N/A-$0.02N/A-$0.02N/A$0.32 million
8/12/2026Q2 2026
Longeveron Inc. stock logo
LGVN
Longeveron
-$1.75-$0.19+$1.56-$1.90$0.33 million$0.29 million
8/6/2026Q2 2026
MetaVia Inc. stock logo
MTVA
MetaVia
-$0.82-$0.90-$0.08-$0.90N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Longeveron Inc. stock logo
LGVN
Longeveron
N/AN/AN/AN/AN/A
MetaVia Inc. stock logo
MTVA
MetaVia
N/AN/AN/AN/AN/A
OSR Holdings, Inc. stock logo
OSRH
OSR
N/AN/AN/AN/AN/A
Valion Bio, Inc. Common Stock stock logo
VBIO
Valion Bio, Inc. Common Stock
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Longeveron Inc. stock logo
LGVN
Longeveron
N/A
2.63
2.63
MetaVia Inc. stock logo
MTVA
MetaVia
N/A
2.06
2.06
OSR Holdings, Inc. stock logo
OSRH
OSR
N/A
0.18
0.14
Valion Bio, Inc. Common Stock stock logo
VBIO
Valion Bio, Inc. Common Stock
1.74
1.11
0.86

Institutional Ownership

CompanyInstitutional Ownership
Longeveron Inc. stock logo
LGVN
Longeveron
10.01%
MetaVia Inc. stock logo
MTVA
MetaVia
1.37%
OSR Holdings, Inc. stock logo
OSRH
OSR
55.30%
Valion Bio, Inc. Common Stock stock logo
VBIO
Valion Bio, Inc. Common Stock
4.25%

Insider Ownership

CompanyInsider Ownership
Longeveron Inc. stock logo
LGVN
Longeveron
7.42%
MetaVia Inc. stock logo
MTVA
MetaVia
0.60%
OSR Holdings, Inc. stock logo
OSRH
OSR
36.90%
Valion Bio, Inc. Common Stock stock logo
VBIO
Valion Bio, Inc. Common Stock
2.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Longeveron Inc. stock logo
LGVN
Longeveron
383.19 million2.95 millionNot Optionable
MetaVia Inc. stock logo
MTVA
MetaVia
85.16 million5.13 millionN/A
OSR Holdings, Inc. stock logo
OSRH
OSR
N/A35.12 million22.16 millionN/A
Valion Bio, Inc. Common Stock stock logo
VBIO
Valion Bio, Inc. Common Stock
10890,000866,000Not Optionable

Recent News About These Companies

Valion Bio, Inc. Announces Appointment of Dean Zikria as Interim Chief Executive Officer
 |  marketscreener.comM
Valion Appoints Life Sciences Veteran Dean Zikria as Interim CEO and Announces Board Leadership Transitions
September 23 at 8:00 AM  |  accessnewswire.comA
Valion Bio, Inc.: Valion Bio Regains Compliance with NASDAQ Minimum Bid Price Listing Rule
September 23 at 4:09 AM  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-09/69644124-valion-bio-inc-valion-bio-regains-compliance-with-nasdaq-minimum-bid-price-listing-rule-200.htm
Valion Bio Regains Compliance with NASDAQ Minimum Bid Price Listing Rule
September 22 at 8:00 AM  |  accessnewswire.comA
VBIO - Valion Bio, Inc.
September 10, 2026  |  seekingalpha.comhttps://seekingalpha.com/symbol/VBIO/historical-price-quotes
Valion Bio Announces Changes to Management and Board of Directors
September 1, 2026  |  accessnewswire.comA
Valion Bio's Reverse Stock Split Takes Effect Today, August 31, 2026; Stock Up
August 31, 2026  |  rttnews.comhttps://www.rttnews.com/3687070/valion-bio-s-reverse-stock-split-takes-effect-today-august-31-2026-stock-up.aspx
Valion Bio, Inc.: Valion Bio Announces Reverse Stock Split
August 27, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69425881-valion-bio-inc-valion-bio-announces-reverse-stock-split-200.htm
Valion Bio Inc VBIO
August 25, 2026  |  morningstar.comM
Valion Bio, Inc. (VBIO)
August 19, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/quote/VBIO/key-statistics/
Valion Bio Inc.
August 17, 2026  |  money.usnews.comhttps://money.usnews.com/investing/stocks/vbio-valion-bio-inc/vitals
Ukraine's Ministry Of Health Advances Entolimod Review Into Technical Assessment Phase
August 13, 2026  |  accessnewswire.comA
Valion Bio Announces U.S. Government-Funded Entolimod Studies Targeting Lethal Radiation-Induced GI Injury
August 12, 2026  |  accessnewswire.comA
Valion Bio, Inc.
July 22, 2026  |  cnn.comhttps://www.cnn.com/markets/stocks/VBIO
Ukraine Ministry of Health Accepts Entolimod Dossier for Formal Review Under Regulatory Equivalence Pathway
July 22, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/ukraine-ministry-of-health-accepts-entolimod-dossier-for-formal-review-under-regulatory-equivalence-pathway-302832086.html
World-Premier Cancer Center Sheba Medical Center Selects Entolimod for Clinical Trial, Potentially Expanding Valion Bio into the Multi-Billion-Dollar Neutropenia Market
July 20, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/world-premier-cancer-center-sheba-medical-center-selects-entolimod-for-clinical-trial-potentially-expanding-valion-bio-into-the-multi-billion-dollar-neutropenia-market-302829829.html
Valion Bio Advances Integrated Biodefense and Immunology Platform Through Continued Government Engagement, Domestic Manufacturing and Oncology Expansion
July 14, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/valion-bio-advances-integrated-biodefense-and-immunology-platform-through-continued-government-engagement-domestic-manufacturing-and-oncology-expansion-302824523.html
AFRRI/NIAID Designs Proprietary PBI-BM2.5 Protocol to Evaluate Valion Bio's (NASDAQ: VBIO) Entolimod as the First and Only Treatment for GI-ARS
June 25, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/afrriniaid-designs-proprietary-pbi-bm2-5-protocol-to-evaluate-valion-bios-nasdaq-vbio-entolimod-as-the-first-and-only-treatment-for-gi-ars-302810088.html
VALION BIO BRIEFS SENIOR DEPARTMENT OF WAR AND BARDA OFFICIALS IN JOINT ENGAGEMENT ON ENTOLIMOD FOR ACUTE RADIATION SYNDROME
May 19, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/valion-bio-briefs-senior-department-of-war-and-barda-officials-in-joint-engagement-on-entolimod-for-acute-radiation-syndrome-302776806.html
Valion Bio, Inc.: Valion Bio Reports First Quarter 2026 Financial Results
May 15, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-05/68505866-valion-bio-inc-valion-bio-reports-first-quarter-2026-financial-results-008.htm

New MarketBeat Followers Over Time

Media Sentiment Over Time

Longeveron stock logo

Longeveron NASDAQ:LGVN

$2.80 -0.11 (-3.85%)
As of 01:38 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.

MetaVia stock logo

MetaVia NASDAQ:MTVA

$1.65 +0.02 (+1.29%)
As of 01:35 PM Eastern
This is a fair market value price provided by Massive. Learn more.

MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc., formerly known as NeuroBo Pharmaceuticals Inc., is based in CAMBRIDGE, Mass.

OSR stock logo

OSR NASDAQ:OSRH

$0.22 -0.04 (-14.23%)
As of 01:01 PM Eastern

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D "platform technologies" versus "assets only" companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea.

Valion Bio, Inc. Common Stock stock logo

Valion Bio, Inc. Common Stock NASDAQ:VBIO

$2.97 -0.51 (-14.66%)
As of 01:21 PM Eastern

Tivic Health Systems Inc. operates as a health tech company, focuses on developing and commercializing bioelectronic medicine. Its primary product is ClearUP, a bioelectronic medicine for the treatment of sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S. online retailers, such as BestBuy and FSAStore and through distributors. Tivic Health Systems, Inc. was incorporated in 2016 and is headquartered in Hayward, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas